New Technologies for Cardiac CT. Geoffrey D. Rubin, MD, MBA, FACR, FNASCI Duke University

Similar documents
Εξελίξεις και νέες προοπτικές στην καρδιαγγειακή απεικόνιση CT. Σταμάτης Κυρζόπουλος Ωνάσειο Καρδιοχειρουργικό Κέντρο

MEDICAL UNIVERSITY of SOUTH CAROLINA

New Stable Chest Pain Guidance in the UK NICE to have, difficult to implement

The Role of Computed Tomography in the Diagnosis of Coronary Atherosclerosis

Ultrasound. Computed tomography. Case studies. Utility of IQon Spectral CT in. cardiac imaging

CT FFR: Are you ready to totally change the way you diagnose Coronary Artery Disease?

The Emerging Role of Cardiac CT in Cardiovascular Imaging. Anthony Gemignani, MD Vermont Cardiac Network April 28, 2016

Optimal testing for coronary artery disease in symptomatic and asymptomatic patients

Which Test When? Avoid the Stress of Stress Testing. Marc Newell, MD, FACC, FSCCT Minneapolis Heart Institute

Current and Future Imaging Trends in Risk Stratification for CAD

FFR-CT Not Ready for Primetime

Multimodality Cardiac Imaging: Its Use in the Era of Value-based Reimbursement

Is computed tomography angiography really useful in. of coronary artery disease?

Pamela S. Douglas, Gianluca Pontone, Mark A. Hlatky, Manesh R. Patel, Campbell Rogers, Bernard De Bruyne. On behalf of the PLATFORM Investigators

Fundamentals, Techniques, Pitfalls, and Limitations of MDCT Interpretation and Measurement

Recent Advances in Nuclear Cardiology, Cardiac CT, and Cardiac MRI: Applications for CAD in the Era of Value-based Imaging

Reducing the Population Health Burden of Cardiovascular Disease

Coronary Artery Disease - Reporting and Data System (CAD-RADS)

The 2016 NASCI Keynote: Trends in Utilization of Cardiac Imaging: The Coronary CTA Conundrum. David C. Levin, M.D.

Multidetector CT Angiography for the Detection of Left Main Coronary Artery Disease. Rani K. Hasan, M.D. Intro to Clinical Research July 22 nd, 2011

Cardiac CT Angiography

Cardiac Computed Tomography

Usefulness of New CT Technologies for Interventional Cardiovascular Procedures

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Computed Tomography of the Coronary Arteries

Advanced Imaging MRI and CTA

Patient referral for elective coronary angiography: challenging the current strategy

2/20/2013. Why use imaging in CV prevention? Update on coronary CTA in 2013 Coronary CTA for 1 0 prevention: pros and cons Are we there yet?

Diagnostic and prognostic benefits of CTCA using the 2016 NICE guidance within a randomised trial

How to investigate (Cardiac) Chest Pain

b. To facilitate the management decision of a patient with an equivocal stress test.

Impact of SSF on diagnostic performance of coronary CT angiography within one heart beat in patients with high heart rate using a 256-row detector CT

Dual-Energy CT: The Technological Approaches

Diagnosis of CAD S Richard Underwood

Troponin = 35. Objectives. Low Risk Chest Pain. Does this patient have ACS? Does this patient have ACS? Objectives

Imaging of the Heart Todd Tessendorf MD FACC

The NICE chest pain guideline 1 year on. Jane S Skinner Consultant Community Cardiologist The Newcastle upon Tyne Hospitals NHS Foundation Trust

Disclosure Information

Overview. Health and economic burden of coronary artery disease (CAD) Pitfalls in care of patients suspected of having CAD

When Should I Order a Stress Test or an Echocardiogram

Les Outils Cliniques de Demain en Scanner Cardiaque. Cardiaque Status en ECR 2018 From Diagnosis to Prognosis

Physiologic Assessment by Cardiac CT

Test in Subjects with Suspected CAD Anatomic Study is Better

Prior Authorization Review Panel MCO Policy Submission

CT Imaging of Atherosclerotic Plaque. William Stanford MD Professor-Emeritus Radiology University of Iowa College of Medicine Iowa City, IA

Alessandro Albonico Philips

Multisclice CT in combination with functional imaging for CAD. Temporal Resolution. Spatial Resolution. Temporal resolution = ½ of the rotation time

Chest Pain. Dr Robert Huggett Consultant Cardiologist

Recent Clinical Trials in CCTA Implica3ons for Prac3ce

Evidence for Everyone: Expanding the Reach of Health Technology Assessment 2016 CADTH Symposium, April 10-12, Shaw Centre, Ottawa

CARDIAC IMAGING FOR SUBCLINICAL CAD

CT Perfusion. U. Joseph Schoepf, MD, FAHA, FSCBT MR, FSCCT Professor of Radiology, Medicine, and Pediatrics Director of Cardiovascular Imaging

Cardiac CT Techniques in Neonates (and infants)

Simon A. Mahler MD, MS, FACEP Associate Professor Department of Emergency Medicine Wake Forest School of Medicine

A Randomized Comparison of Anatomic versus Functional Diagnostic Testing Strategies in Symptomatic Patients with Suspected Coronary Artery Disease

Dual Energy CT of the Heart: Perfusion and Beyond

CARDIAC MULTIMODALITY IMAGING: Informing better decisions - or just costly pictures?

CASE from South Korea

Risk Stratification for CAD for the Primary Care Provider

Cardiac Stress MRI: Detection of Ischemia. Disclosures: Dobutamine Stress MR. April 28, 2018

CT or PET/CT for coronary artery disease

AORTIC VALVE CASES. Richard L. Hallett, MD

Coronary Artery Imaging. Suvipaporn Siripornpitak, MD Inter-hospital Conference : Rajavithi Hospital

The Value of Stress MRI in Evaluation of Myocardial Ischemia

I have no financial disclosures

Calcium scoring Clinical and prognostic value

CT Myocardial Perfusion: Is there Added Value to Coronary CT?

The Final 10-Year Follow-up Results from the Bari Randomized Trial J Am Coll Cardiol (2007) 49;1600-6

Low Dose Era in Cardiac CT

MEDICAL POLICY No R1 COMPUTERIZED TOMOGRAPHIC ANGIOGRAPHY CORONARY ARTERIES (CCTA)

MEDICAL POLICY No R2 COMPUTERIZED TOMOGRAPHIC ANGIOGRAPHY CORONARY ARTERIES (CCTA)

Covered Indications. Evaluation of chest pain syndrome uninterpretable or equivocal stress test (exercise, perfusion, or stress echo)

Patient preparation and coronary CTA techniques. Gregory Kicska, M.D. Ph.D. University of Washington, Thoracic Imaging

Welcome! To submit questions during the presentation: or Text:

, David Stultz, MD. Cardiac CT. David Stultz, MD Cardiology Fellow, PGY 6 March 28, 2006

Dr Chris Ellis Cardiologist, Auckland City Hospital

MEDICAL POLICY. Proprietary Information of Excellus Health Plan, Inc. A nonprofit independent licensee of the BlueCross BlueShield Association

Imaging ischemic heart disease: role of SPECT and PET. Focus on Patients with Known CAD

Management of stable CAD FFR guided therapy: the new gold standard

. θωρακικούάλγουςστα εξωτερικά ιατρεία

2019 Qualified Clinical Data Registry (QCDR) Performance Measures

CardioLucca2014. Fare luce sulla scelta ottimale del trattamento nella rivascolarizzazione delle stenosi carotidee. Fabrizio Tomai

Certainty. lives in layers. Philips IQon Spectral CT. Computed tomography

Hybrid cardiac imaging Advantages, limitations, clinical scenarios and perspectives for the future

Computer Aided Detection and Diagnosis: Cardiac Imaging Applications

Low-dose and High-resolution Cardiac Imaging with Revolution CT

Chest pain. One problem different approaches... Question 1 what is your choice? In-/Exclusion Criteria

Evidence-Based Management of CAD: Last Decade Trials and Updated Guidelines

MEDICAL POLICY. Proprietary Information of Excellus Health Plan, Inc. A nonprofit independent licensee of the BlueCross BlueShield Association

CMR stress Perfusion: what's new?

ROMICAT II - Rule Out Myocardial

Cardiac CT Lowering the Dose Dramatically

Combined Anatomical and Functional Imaging with Revolution * CT

ESC CONGRESS 2010 Stockholm, august 28 september 1, 2010

What oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor

Multimodality Imaging in Spontaneous Coronary Artery Dissection in the Peripartum Period

Diagnostic Algorithms

High Value Evaluation of Chest Pain. Zoom Tips

Noncoronary Cardiac MDCT

Fellows on this rotation are expected to attend nuclear conferences and multimodality imaging conference.

Transcription:

1996 New Technologies for Cardiac CT Geoffrey D. Rubin, MD, MBA, FACR, FNASCI Duke University

New Technology The Long View Levels of Efficacy Endpoint Examples 1: Technical Imaging resolution 2: Diagnostic Accuracy Sensitivity/specificity 3: Diagnostic Thinking Pre- and post-test changes in subjectively determined outcome 4: Therapeutic Effects on choice of therapy 5: Patient Outcome Impact of test information on morbidity, mortality, and QALYs 6: Societal Cost-benefit/effectiveness for society Frybach & Thornbury. Med Decis Making 1991;11:88-94

Reporting Templates Cardiac CT CT Scanner Contrast Injector Advanced Visualization and Analysis Software

Reporting Templates Evidence Base Cardiac CT CT Scanner Contrast Injector Evidence Base Advanced Visualization and Analysis Software

So What s New in 2015? Acquisition Technologies Advanced Visualization/Analysis Evolution of Dual Source FFRCT Wide Area Detector CT Perfusion Maps Multi-layer detector for spectral Evidence Base CT ED Clinical Trials Contrast dose and delivery Stable chest pain trials Iterative Reconstruction FFRCT Trials

So What s New in 2015? Acquisition Technologies Advanced Visualization/Analysis Evolution of Dual Source FFRCT Wide Area Detector CT Perfusion Maps Multi-layer detector for spectral Evidence Base CT ED Clinical Trials Contrast dose and delivery Stable chest pain trials Iterative Reconstruction FFRCT Trials

So What s New in 2015? 3D Printing Information Technology Visualization ACRSelect decision support Planning Graft creation PACS, RIS, reporting system, EMR integration Image Sharing Transcatheter Valve Prostheses Aortic Mitral Univ College Dublin

Contrast Delivery Management System Centralized server PACS/RIS integration Protocol management Recording and archive of injection parameters Performance metrics for resource utilization, operations, safety

Dual-energy (spectral) CT Technologies Applications Dual source Contrast medium dose reduction Fast kv switching Metal artifact reduction Dual layer detector Material decomposition Serial single-energy scans Calcium iodine separation 4D Cardiac most challenging, but gains are being made

Dual-energy (spectral) CT Carrascosa et al, Eur J Radiol 2015

Dual-energy (spectral) CT Virtual Unenhanced True Unenhanced Virtual 50 kev Pinho et al, Eur Radiol 2013; 23:351

Dual-energy (spectral) CT Rodriguez-Granillo et al, Card Diagn Ther 2015; 5:79

Coronary CTA Evidence Base Acute Coronary Syndrome ROMICAT II high risk plaque predicts ACS independent of % stenosis Puchner et al, JACC 2014; 64:684 Chest pain in outpatients PROMISE SCOT-HEART PLATFORM

10,003 patients with new onset chest pain (not ACS) randomized to standard functional testing or CCTA Pragmatic trial design 64-row CT scanners CTA Functional CTA Strategy Strategy Strategy Nuclear CTA Stress 93.8% 67.5% 0.9% Stress Echo2.9% 22.4% 93.7% Patients followed for median of 2.0 (range 1.0-4.2) yrs. Exercise No Test ECG3.1% 10.2%% 4.9%

PROMISE Outcomes Primary Composite End Point Death (any cause) MI Hospitalized for unstable angina Major procedural complications

PROMISE Outcomes CT Strategy (N=4996) Functional-Testing Strategy (N=5007) P Value Primary Composite End Point 3.3% 3.0% 0.75 Cardiac Catheterization 12.2% 8.1% Catheterization showing no obstructive CAD 3.4% 4.3% 0.02 Revascularization 6.2% 3.2% <0.001

SCOT-HEART David Newby, PI Lancet 2015; 385: 2383 91 4,146 patients with chest pain randomized to standard care or standard care + CCTA Pragmatic trial design 64-row or 320-row CT scanners Patients followed for median of 1.7 (range 0.1-4.1) years

SCOT HEART: Invasive Procedures Median 1.7 Years of Follow-up Coronary Angiography Coronary Revascularisation 25 HR 1.06 [0.92-1.21], P=0.451 HR 1.20 [0.99-1.45], P=0.061 Proportion of patients with an event (%) 20 CTCA 15 10 5 Standard Care Proportion of patients with an event (%) 15 10 Cumulative incidence, % 5 15% 10% 5% CTCA Standard Care strata AllocatedTreatment=2 AllocatedTreatment=1 CTCA Standard Care 0 2073 1249 634 227 2073 1263 660 226 CTCA Standard Care 0 0% 2073 1386 733 270 2073 1413 755 276 0 500 1000 1500 Time, days 0 1 2 3 0 1 2 3 Follow Up Follow Up (years) (years)

SCOT Heart: Clinical Outcomes Median 1.7 Years of Follow-up CHD Death & Non-Fatal MI CHD Death, Non-Fatal MI & Stroke 5 5% HR 0.62 [0.38-1.01], P=0.053 5 5% HR 0.64 [0.41-1.01], P=0.056 Proportion of patients with an event (%) 4 3 2 1 Cumulative incidence, % 4% 3% 2% 1% Standard Care CTCA strata AllocatedTreatment=2 AllocatedTreatment=1 Proportion of patients with an event (%) 4 3 2 1 Cumulative incidence, % 4% 3% 2% 1% Standard Care CTCA strata AllocatedTre AllocatedTre 0 CTCA Standard Care 0% 2073 1571 853 323 2073 1550 837 316 0 500 1000 1500 Time, days 0 CTCA Standard Care 0% 2073 1569 851 321 2073 1547 835 315 0 500 1000 1500 Time, days 0 1 2 3 Follow Up (years) 0 1 2 3 Follow Up (years)

SCOT Heart: Conclusions Regarding CCTA Increases dx of CHD Does not affect short-term anginal symptoms May increase coronary revascularization (9.7 vs 11.2%, 1.5% increase) May reduce MI (1.3 vs 2.0%, 0.7% reduction)

398,978 pts w/ suspected CAD to Cath (663 U.S. hospitals over 4 years) 37.6% had obstructive CAD 39.2% were normal N Engl J Med 2010;362:886-95

Non-Obst. CAD Obstructive CAD No ICA PLATFORM Trial Eur Heart J. 2015 NI Test Planned ICA Planned Usual Care FFRCT Usual Care FFRCT 100% 100% Key Results 90% 90% FFRCT vs. U.C. 27% 80% 80% No No cath in 61% 70% 70% 73% events 60% 60% at 90 Same % (+) caths 50% 50% days 40% 40% 6x less (-) caths 30% 30% 27% 20% 12% 18% 20% No sig increase in 10% 10% 12% downstream cath 0% 0% n=100 n=104 n=187 n=193 P = 0.95 P < 0.0001

Summary Cardiac CT Technology Think Long Think Broad Think Value patient imager

Technology I Want to be Discussing Heart rate independent cardiac motion-free acquisition Automated optimized protocol definition based on CT measured biometrics (wt, body contour/composition, HR, ) Comprehensive preprocessing with integrated volume rendering, MPR, & annotated quantization of stenosis and plaque character. Automated prior exam analysis for assessment of all non-normal findings Comprehensive intuitive data display with pre-population of reporting template